Different genetic and epigenetic alterations in SS are described and, despite the heterogeneous findings, they converge to the JAK/STAT pathway alterations, with an increased STAT3, STAT5, and STAT6 and decreased STAT4 activation. The gene discussed is STAT6; the disease is synovial sarcoma.